| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy® |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results |
| 17 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, ARS Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 27, 2026, the record date for the Annual Meeting, 99,300,658 shares of common stock were outstan... |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Q1 2026 total revenue of $22.7 million including neffy U.S. net product revenue of $17.5 million |
| 13 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Executive Employment Agreement (this “Agreement”) is made and entered into effective as of May 12, 2026 (the “Effective Date”), by and between Donn Casale (“Executive”) and ARS Pharmaceuticals, Inc. (the “Company”). |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 |
| 29 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFI... |
| 28 Aug 2025 |
8-K: Other Events
On August 13, 2025, ARS Pharmaceuticals, Inc. (the “Company”) received a Paragraph IV certification notice (the “Notice”) from Lupin Inc. (“Lupin”), advising that Lupin has submitted to the U.S. Food and Drug Administration (the “FDA”) a... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) |
| 26 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 25, 2025, ARS Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 28, 2025, the record date for the Annual Meeting, 98,210,512 shares of common stock were outstan... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) |
| 02 May 2025 |
8-K: Entry into a Material Definitive Agreement
On May 2, 2025, ARS Pharmaceuticals, Inc. (“ARS”), through its wholly owned subsidiary ARS Pharmaceuticals Operations, Inc. (the “Company”), and ALK-Abelló, Inc. (“ALK”) entered into a co-promotion agreement (the “Co-Promotion Agreement”... |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 |
| 05 Mar 2025 |
8-K: Other Events
On March 5, 2025, ARS Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) approved neffy 1 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including ... |
| 13 Jan 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
Commercial launch of neffy® (epinephrine nasal spray) underway in the United States |
| 12 Nov 2024 |
8-K: Entry into a Material Definitive Agreement
On November 9, 2024, ARS Pharmaceuticals, Inc. (“ARS”), through its wholly owned subsidiary ARS Pharmaceuticals Operations, Inc. (the “Company”), entered into a collaboration, license and distribution agreement (the “Collaboration Agreem... |
Loading...